This article has been reviewed according to Science X's editorial process and policies. Editors have highlighted the following attributes while ensuring the content's credibility:
A new study led by experts at the University of Nottingham has provided new insight into how a commonly used test for colorectal cancer performs in people under 50.
Colorectal cancer is the fourth most common cancer and second-leading cause of cancer death in the U.K. (according to Cancer Research UK). Globally, there has been a concerning increase in "early-onset" colorectal cancer (i.e., a diagnosis before age 50), which highlights the importance of improving diagnosis in younger people.
This new study, published in the journal Gut, looked at whether FITs (fecal immunochemical tests) are effective tests for bowel cancer (colorectal cancer) in people under 50.
The study was led by professor David Humes in the School of Medicine and NIHR Nottingham Biomedical Research Centre and supported by international collaborators including COLOREACH-UK and the U.S.-based charity Fight Colorectal Cancer.
The results indicate that further work is needed to understand how a person's age should be considered alongside their FIT results to better determine colorectal cancer risk and prioritize investigation of those most at risk.
FITs are used by general practitioners to detect microscopic traces of blood in the stool of people who have symptoms of colorectal cancer. If the test is "negative," then the risk of colorectal cancer is very low, and no further tests are needed.
If the FIT result is 10 or above, patients are referred to the hospital for urgent further tests, such as a camera test ( colonoscopy ), which is invasive and can be uncomfortable.
Source link







